NasdaqCM:MTEM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Molecular Templates's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MTEM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-12.6%

MTEM

-1.2%

US Biotechs

0.4%

US Market


1 Year Return

13.9%

MTEM

32.5%

US Biotechs

17.8%

US Market

Return vs Industry: MTEM underperformed the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: MTEM underperformed the US Market which returned 17.8% over the past year.


Shareholder returns

MTEMIndustryMarket
7 Day-12.6%-1.2%0.4%
30 Day-7.7%2.3%6.1%
90 Day-16.8%-2.6%8.9%
1 Year13.9%13.9%34.7%32.5%20.5%17.8%
3 Year21.6%21.6%20.0%14.0%42.3%32.9%
5 Yearn/a11.5%3.4%84.2%63.4%

Price Volatility Vs. Market

How volatile is Molecular Templates's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Molecular Templates undervalued compared to its fair value and its price relative to the market?

7.92x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MTEM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MTEM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MTEM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MTEM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MTEM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MTEM is overvalued based on its PB Ratio (7.9x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Molecular Templates forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

6.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MTEM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MTEM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MTEM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MTEM's revenue (36.2% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MTEM's revenue (36.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MTEM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Molecular Templates performed over the past 5 years?

-51.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MTEM is currently unprofitable.

Growing Profit Margin: MTEM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MTEM is unprofitable, and losses have increased over the past 5 years at a rate of 51.5% per year.

Accelerating Growth: Unable to compare MTEM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MTEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: MTEM has a negative Return on Equity (-192.17%), as it is currently unprofitable.


Next Steps

Financial Health

How is Molecular Templates's financial position?


Financial Position Analysis

Short Term Liabilities: MTEM's short term assets ($108.1M) exceed its short term liabilities ($41.4M).

Long Term Liabilities: MTEM's short term assets ($108.1M) exceed its long term liabilities ($45.2M).


Debt to Equity History and Analysis

Debt Level: MTEM's debt to equity ratio (26.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MTEM's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MTEM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MTEM has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 41.3% each year.


Next Steps

Dividend

What is Molecular Templates's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MTEM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MTEM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MTEM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MTEM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MTEM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Eric Poma (48 yo)

11.75yrs

Tenure

US$1,733,738

Compensation

Dr. Eric E. Poma, Ph.D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as it's President. Dr. Poma served as Vice President of Business Deve ...


CEO Compensation Analysis

Compensation vs Market: Eric's total compensation ($USD1.73M) is about average for companies of similar size in the US market ($USD1.93M).

Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Eric Poma
CEO, Chief Scientific Officer & Director11.75yrsUS$1.73m0.48%
$ 2.3m
Jason Kim
President & COO10.75yrsUS$1.08m0.11%
$ 523.5k
Roger Waltzman
Chief Medical Officer1.67yrsUS$1.32m0%
$ 0
Adam Cutler
Chief Financial Officer2.92yrsUS$1.07m0%
$ 0
Kurt Elster
Executive Vice President of Corporate Developmentno datano datano data
Jack Higgins
Executive VP of Operations & Head of Manufacturingno datano datano data
Erin Willert
Executive Vice President of R&Dno datano datano data
Jen-Sing Liu
Executive Vice President of Manufacturingno datano datano data
Nenad Sarapa
Senior Vice President of Clinical Development2.92yrsno datano data
Conrad Jordaan
Senior Vice President of Finance & Corporate Controller2.92yrsno datano data

2.9yrs

Average Tenure

47yo

Average Age

Experienced Management: MTEM's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eric Poma
CEO, Chief Scientific Officer & Director11.75yrsUS$1.73m0.48%
$ 2.3m
Michel Klein
Member of Scientific Advisory Boardno datano datano data
David Hoffmann
Independent Director3.17yrsUS$157.55k0%
$ 0
Harold Selick
Independent Chairmanno dataUS$172.55k0.082%
$ 394.6k
Kevin Lalande
Independent Directorno dataUS$160.55k0%
$ 0
Corazon Dating Sanders
Independent Director0.83yrUS$263.07kno data
David Hirsch
Independent Director3.17yrsUS$159.05k0.0033%
$ 15.9k
Burkhard Jansen
Member of Scientific Advisory Boardno datano datano data
Neil Berinstein
Member of Scientific Advisory Boardno datano datano data
Jonathan Lanfear
Independent Director2.42yrsno datano data
Scott Morenstein
Independent Director3.17yrsUS$150.05k0%
$ 0

3.2yrs

Average Tenure

52.5yo

Average Age

Experienced Board: MTEM's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MTEM insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.1%.


Top Shareholders

Company Information

Molecular Templates, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Molecular Templates, Inc.
  • Ticker: MTEM
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$482.719m
  • Shares outstanding: 49.92m
  • Website: https://www.mtem.com

Number of Employees


Location

  • Molecular Templates, Inc.
  • 9301 Amberglen Boulevard
  • Suite 100
  • Austin
  • Texas
  • 78729
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MTEMNasdaqCM (Nasdaq Capital Market)YesNew Common SharesUSUSDAug 2017
NZW2DB (Deutsche Boerse AG)YesNew Common SharesDEEURAug 2017

Biography

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company’s propri ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 05:21
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.